Vera Therapeutics, Inc.
VERA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | -$846 | $0 |
| Gross Profit | $0 | $0 | $846 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $126,172 | $78,225 | $69,839 | $22,484 |
| G&A Expenses | $40,998 | $23,787 | $0 | $11,918 |
| SG&A Expenses | $40,998 | $23,787 | $21,910 | $11,918 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $167,170 | $102,012 | $91,749 | $34,402 |
| Operating Income | -$167,170 | -$102,012 | -$90,903 | -$34,402 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $15,023 | $6,023 | $1,848 | $1,794 |
| Pre-Tax Income | -$152,147 | -$95,989 | -$89,055 | -$32,608 |
| Tax Expense | $1 | $1 | $1 | $1 |
| Net Income | -$152,148 | -$95,990 | -$89,056 | -$32,609 |
| % Margin | – | – | – | – |
| EPS | -2.75 | -2.25 | -3.35 | -2.43 |
| % Growth | -22.2% | 32.8% | -37.9% | – |
| EPS Diluted | -2.75 | -2.25 | -3.35 | -2.43 |
| Weighted Avg Shares Out | 55,327 | 42,707 | 26,571 | 13,436 |
| Weighted Avg Shares Out Dil | 55,327 | 42,707 | 26,571 | 13,436 |
| Supplemental Information | – | – | – | – |
| Interest Income | $20,714 | $7,979 | $1,750 | $15 |
| Interest Expense | $7,626 | $3,786 | $992 | $20 |
| Depreciation & Amortization | $105 | $21 | -$846 | $176 |
| EBITDA | -$144,416 | -$92,182 | -$88,909 | -$32,412 |
| % Margin | – | – | – | – |